36 results on '"Busceti, Maria Teresa"'
Search Results
2. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study
- Author
-
Pelaia, Corrado, Calabrese, Cecilia, Barbuto, Sarah, Busceti, Maria Teresa, Preianò, Mariaimmacolata, Gallelli, Luca, Savino, Rocco, Vatrella, Alessandro, and Pelaia, Girolamo
- Published
- 2019
- Full Text
- View/download PDF
3. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
- Author
-
Pelaia, Corrado, Busceti, Maria Teresa, Solinas, Sabina, Terracciano, Rosa, and Pelaia, Girolamo
- Published
- 2018
- Full Text
- View/download PDF
4. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
- Author
-
Pelaia, Corrado, primary, Benfante, Alida, additional, Busceti, Maria Teresa, additional, Caiaffa, Maria Filomena, additional, Campisi, Raffaele, additional, Carpagnano, Giovanna Elisiana, additional, Crimi, Nunzio, additional, D’Amato, Maria, additional, Foschino Barbaro, Maria Pia, additional, Maglio, Angelantonio, additional, Minenna, Elena, additional, Nolasco, Santi, additional, Paglino, Giuseppe, additional, Papia, Francesco, additional, Pelaia, Girolamo, additional, Portacci, Andrea, additional, Ricciardi, Luisa, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Triggiani, Massimo, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, and Crimi, Claudia, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey
- Author
-
Braido, Fulvio, Baiardini, Ilaria, Alleri, Pietro, Bacci, Elena, Barbetta, Carlo, Bellocchia, Michela, Benfante, Alida, Blasi, Francesco, Bucca, Caterina, Busceti, Maria Teresa, Centanni, Stefano, Colanardi, Maria Cristina, Contoli, Marco, Corsico, Angelo, D'Amato, Maria, Di Marco, Fabiano, Marco, Dottorini, Ferrari, Marta, Florio, Giovanni, Fois, Alessandro Giuseppe, Foschino Barbaro, Maria Pia, Silvia, Garuti, Girbino, Giuseppe, Grosso, Amelia, Latorre, Manuela, Maniscalco, Sara, Mazza, Francesco, Mereu, Carlo, Molinengo, Giorgia, Ora, Josuel, Paggiaro, Pierluigi, Patella, Vincenzo, Pelaia, Girolamo, Pirina, Pietro, Proietto, Alfio, Rogliani, Paola, Santus, Pierachille, Scichilone, Nicola, Simioli, Francesca, Solidoro, Paolo, Terraneo, Silvia, Zuccon, Umberto, and Canonica, Giorgio Walter
- Published
- 2017
- Full Text
- View/download PDF
6. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma
- Author
-
Pelaia, Girolamo, Vatrella, Alessandro, Busceti, Maria Teresa, Fabiano, Francesco, Terracciano, Rosa, Matera, Maria Gabriella, and Maselli, Rosario
- Published
- 2016
- Full Text
- View/download PDF
7. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
- Author
-
Pelaia, Corrado, Benfante, Alida, Busceti, Maria Teresa, Caiaffa, Maria Filomena, Campisi, Raffaele, Carpagnano, Giovanna Elisiana, Crimi, Nunzio, D’Amato, Maria, Foschino Barbaro, Maria Pia, Maglio, Angelantonio, Minenna, Elena, Nolasco, Santi, Paglino, Giuseppe, Papia, Francesco, Pelaia, Girolamo, Portacci, Andrea, Ricciardi, Luisa, Scichilone, Nicola, Scioscia, Giulia, Triggiani, Massimo, Valenti, Giuseppe, Vatrella, Alessandro, and Crimi, Claudia
- Subjects
Immunology ,Immunology and Allergy - Abstract
BackgroundThe efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.ObjectiveTo assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence.MethodsClinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP.ResultsAmong the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p < 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p < 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 ± 20.32 to 19.76 ± 12.76 (p < 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p < 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p < 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p < 0.01).ConclusionOur results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation.
- Published
- 2023
8. Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis
- Author
-
Pelaia, Corrado, primary, Lombardo, Nicola, additional, Busceti, Maria Teresa, additional, Dragone, Alessia, additional, Piazzetta, Giovanna Lucia, additional, Crimi, Claudia, additional, Vatrella, Alessandro, additional, and Pelaia, Girolamo, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
- Author
-
Pelaia, Corrado, primary, Lombardo, Nicola, additional, Busceti, Maria Teresa, additional, Piazzetta, Giovanna, additional, Crimi, Claudia, additional, Calabrese, Cecilia, additional, Vatrella, Alessandro, additional, and Pelaia, Girolamo, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility
- Author
-
Trecarichi, Enrico Maria, Mazzitelli, Maria, Serapide, Francesca, Pelle, Maria Chiara, Tassone, Bruno, Arrighi, Eugenio, Perri, Graziella, Fusco, Paolo, Scaglione, Vincenzo, Davoli, Chiara, Lionello, Rosaria, La Gamba, Valentina, Marrazzo, Giuseppina, Busceti, Maria Teresa, Giudice, Amerigo, Ricchio, Marco, Cancelliere, Anna, Lio, Elena, Procopio, Giada, Costanzo, Francesco Saverio, Foti, Daniela Patrizia, Matera, Giovanni, Torti, Carlo, Laganà, Domenico, Petullà, Maria, Bertucci, Bernardo, Quirino, Angela, Barreca, Giorgio Settimo, Giancotti, Aida, Gallo, Luigia, Lamberti, Angelo, Liberto, Maria Carla, Marascio, Nadia, De Francesco, Adele Emanuela, and IDTM UMG COVID-19 Group
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,China ,Epidemiology ,Article ,COVID-19 ,Infectious diseases ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Lymphopenia ,Pandemic ,medicine ,Humans ,030212 general & internal medicine ,Hospital Mortality ,Aged ,Aged, 80 and over ,Multidisciplinary ,Hypernatremia ,Proportional hazards model ,business.industry ,Interleukin-6 ,SARS-CoV-2 ,Mortality rate ,Outbreak ,medicine.disease ,Long-Term Care ,Nursing Homes ,Hospitalization ,Long-term care ,030104 developmental biology ,Cardiovascular Diseases ,Cohort ,Female ,business ,Cytokine Release Syndrome ,Cohort study - Abstract
Since December 2019, coronavirus disease 2019 (COVID-19) pandemic has spread from China all over the world and many COVID-19 outbreaks have been reported in long-term care facilities (LCTF). However, data on clinical characteristics and prognostic factors in such settings are scarce. We conducted a retrospective, observational cohort study to assess clinical characteristics and baseline predictors of mortality of COVID-19 patients hospitalized after an outbreak of SARS-CoV-2 infection in a LTCF. A total of 50 patients were included. Mean age was 80 years (SD, 12 years), and 24/50 (57.1%) patients were males. The overall in-hospital mortality rate was 32%. At Cox regression analysis, significant predictors of in-hospital mortality were: hypernatremia (HR 9.12), lymphocyte count
- Published
- 2020
11. Reviewer_1_v.1 – Supplemental material for Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study
- Author
-
Procopio, Giada, Cancelliere, Anna, Trecarichi, Enrico Maria, Mazzitelli, Maria, Arrighi, Eugenio, Perri, Graziella, Serapide, Francesca, Pelaia, Corrado, Lio, Elena, Busceti, Maria Teresa, Pelle, Maria Chiara, Ricchio, Marco, Scaglione, Vincenzo, Davoli, Chiara, Fusco, Paolo, Gamba, Valentina La, Torti, Carlo, and Pelaia, Girolamo
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, Reviewer_1_v.1 for Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study by Giada Procopio, Anna Cancelliere, Enrico Maria Trecarichi, Maria Mazzitelli, Eugenio Arrighi, Graziella Perri, Francesca Serapide, Corrado Pelaia, Elena Lio, Maria Teresa Busceti, Maria Chiara Pelle, Marco Ricchio, Vincenzo Scaglione, Chiara Davoli, Paolo Fusco, Valentina La Gamba, Carlo Torti and Girolamo Pelaia in Therapeutic Advances in Respiratory Disease
- Published
- 2020
- Full Text
- View/download PDF
12. Author_Response – Supplemental material for Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study
- Author
-
Procopio, Giada, Cancelliere, Anna, Trecarichi, Enrico Maria, Mazzitelli, Maria, Arrighi, Eugenio, Perri, Graziella, Serapide, Francesca, Pelaia, Corrado, Lio, Elena, Busceti, Maria Teresa, Pelle, Maria Chiara, Ricchio, Marco, Scaglione, Vincenzo, Davoli, Chiara, Fusco, Paolo, Gamba, Valentina La, Torti, Carlo, and Pelaia, Girolamo
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, Author_Response for Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study by Giada Procopio, Anna Cancelliere, Enrico Maria Trecarichi, Maria Mazzitelli, Eugenio Arrighi, Graziella Perri, Francesca Serapide, Corrado Pelaia, Elena Lio, Maria Teresa Busceti, Maria Chiara Pelle, Marco Ricchio, Vincenzo Scaglione, Chiara Davoli, Paolo Fusco, Valentina La Gamba, Carlo Torti and Girolamo Pelaia in Therapeutic Advances in Respiratory Disease
- Published
- 2020
- Full Text
- View/download PDF
13. New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant
- Author
-
Pelaia, Corrado, primary, Crimi, Claudia, additional, Vatrella, Alessandro, additional, Busceti, Maria Teresa, additional, Gaudio, Achille, additional, Garofalo, Eugenio, additional, Bruni, Andrea, additional, Terracciano, Rosa, additional, and Pelaia, Girolamo, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
- Author
-
Pelaia, Corrado, primary, Busceti, Maria Teresa, additional, Vatrella, Alessandro, additional, Ciriolo, Marco, additional, Garofalo, Eugenio, additional, Crimi, Claudia, additional, Terracciano, Rosa, additional, Lombardo, Nicola, additional, and Pelaia, Girolamo, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study
- Author
-
Procopio, Giada, primary, Cancelliere, Anna, additional, Trecarichi, Enrico Maria, additional, Mazzitelli, Maria, additional, Arrighi, Eugenio, additional, Perri, Graziella, additional, Serapide, Francesca, additional, Pelaia, Corrado, additional, Lio, Elena, additional, Busceti, Maria Teresa, additional, Pelle, Maria Chiara, additional, Ricchio, Marco, additional, Scaglione, Vincenzo, additional, Davoli, Chiara, additional, Fusco, Paolo, additional, La Gamba, Valentina, additional, Torti, Carlo, additional, and Pelaia, Girolamo, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
- Author
-
Pelaia, Corrado, primary, Busceti, Maria Teresa, additional, Vatrella, Alessandro, additional, Rago, Giuseppe Francesco, additional, Crimi, Claudia, additional, Terracciano, Rosa, additional, and Pelaia, Girolamo, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
- Author
-
Pelaia, Corrado, Calabrese, Cecilia, Vatrella, Alessandro, Busceti, Maria Teresa, Garofalo, Eugenio, Lombardo, Nicola, Terracciano, Rosa, and Pelaia, Girolamo
- Subjects
Article Subject ,respiratory tract diseases - Abstract
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
- Published
- 2018
- Full Text
- View/download PDF
18. Real-life treatment of severe eosinophilic asthma with mepolizumab
- Author
-
Pelaia, Corrado, primary, Busceti, Maria Teresa, additional, Solinas, Sabina, additional, Terracciano, Rosa, additional, and Pelaia, Girolamo, additional
- Published
- 2019
- Full Text
- View/download PDF
19. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
- Author
-
Pelaia,Corrado, Vatrella,Alessandro, Busceti,Maria Teresa, Gallelli,Luca, Terracciano,Rosa, Savino,Rocco, and Pelaia,Girolamo
- Subjects
Drug Design, Development and Therapy - Abstract
Corrado Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Rosa Terracciano,3 Rocco Savino,3 Girolamo Pelaia1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, 2Department of Medicine, Surgery and Dentistry, Section of Respiratory Diseases, University of Salerno, Salerno, 3Department of Health Science, University “Magna Græcia” of Catanzaro, Catanzaro, Italy Abstract: Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Moreover, mepolizumab is also currently included within the step 5 of the Global Initiative for Asthma guidelines, as an add-on therapy for severe uncontrolled asthma. The relevant therapeutic benefits detectable in patients with refractory eosinophilic asthma receiving mepolizumab depend on the pivotal pathogenic role played by IL-5 in these subjects. Indeed, IL-5 is the key cytokine responsible for maturation, activation, proliferation, and survival of eosinophils. Therefore, IL-5 represents a strategic molecular target for anti-eosinophilic treatments. By selectively inhibiting the biological actions of IL-5, mepolizumab provides a valuable therapeutic option for patients with severe eosinophilic asthma, refractory to standard treatments including inhaled and even systemic corticosteroids. In particular, the very important advantages linked to the use of mepolizumab in these difficult-to-treat asthmatic individuals have been well documented by several different trials performed worldwide. Keywords: IL-5, severe eosinophilic asthma, mepolizumab
- Published
- 2017
20. Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report.
- Author
-
Pelle, Maria Chiara, Tassone, Bruno, Ricchio, Marco, Mazzitelli, Maria, Davoli, Chiara, Procopio, Giada, Cancelliere, Anna, La Gamba, Valentina, Lio, Elena, Matera, Giovanni, Quirino, Angela, Barreca, Giorgio Settimo, Trecarichi, Enrico Maria, Torti, Carlo, IDTM UMG COVID-19 Group, Arrighi, Eugenio, Bertucci, Bernardo, Busceti, Maria Teresa, Carallo, Claudio, and Costanzo, Francesco Saverio
- Subjects
AUTOIMMUNE hemolytic anemia ,MYOCARDIAL infarction ,COVID-19 ,SYMPTOMS ,SARS-CoV-2 ,ACUTE coronary syndrome - Abstract
Background: In December 2019, a new coronavirus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) spread from China, causing a pandemic in a very short time. The main clinical presentation of SARS-CoV-2 infection (COVID-19, coronavirus disease-2019) is pneumonia, but several cardiovascular complications may also occur (e.g., acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure and cardiogenic shock). Direct or indirect mechanisms induced by SARS-CoV-2 could be implicated in the pathogenesis of these events.Case Presentation: We report herein the third case of COVID-19 autoimmune haemolytic anaemia (AIHA) reported so far, which occurredwithout any other possible explanations in a Caucasian patient. The patient also suffered from ST-elevation myocardial injury.Conclusions: Both complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study
- Author
-
Crimi, Claudia, Nolasco, Santi, Noto, Alberto, Maglio, Angelantonio, Quaranta, Vitaliano Nicola, Di Bona, Danilo, Scioscia, Giulia, Papia, Francesco, Caiaffa, Maria Filomena, Calabrese, Cecilia, D’Amato, Maria, Pelaia, Corrado, Campisi, Raffaele, Vitale, Carolina, Ciampo, Luigi, Dragonieri, Silvano, Minenna, Elena, Massaro, Federica, Gallotti, Lorena, Macchia, Luigi, Triggiani, Massimo, Scichilone, Nicola, Valenti, Giuseppe, Pelaia, Girolamo, Foschino Barbaro, Maria Pia, Carpagnano, Giovanna Elisiana, Vatrella, Alessandro, Crimi, Nunzio, Porto, Morena, Impellizzeri, Pietro, Frazzetto, Valentina, Bonsignore, Martina, Giannì, Concetta, Nardo, Andrea Alessia, Vignera, Fabio, Busceti, Maria Teresa, Lombardo, Nicola, Lacedonia, Donato, Tondo, Pasquale, Soccio, Piera, Irene Quarato, Carla Maria, Montagnolo, Francesca, Salerno, Vittorio, Maselli, Leonardo, Julai, Ernesto, Coppa, Francesco, Grimaldi, Lucia, Julai, Ernesto, Carrieri, Isabella, Sola, Alessio, Balestrino, Marco, Mariniello, Domenica Francesca, Carrieri, Isabella, Benfante, Alida, Spadaro, Giuseppe, Detoraki, Aikaterini, Ricciardi, Luisa, Antonio, Franzese, and Valeria, Longobardi
- Abstract
Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. While mepolizumab's short-term effectiveness is established, there is limited evidence on its ability to achieve long-term clinical remission.
- Published
- 2024
- Full Text
- View/download PDF
22. Role of biologics in severe eosinophilic asthma – focus on reslizumab
- Author
-
PELAIA, GIROLAMO, Vatrella,Alessandro, Busceti,Maria Teresa, GALLELLI,LUCA, Preianò,Mariaimmacolata, Lombardo,Nicola, Terracciano,Rosa, and Maselli,Rosario
- Subjects
Therapeutics and Clinical Risk Management - Abstract
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of Medicine and Surgery, Section of Respiratory Diseases, University of Salerno, Salerno, Italy; 3Department of Health Science, University “Magna Græcia” of Catanzaro, Catanzaro, Italy Abstract: Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. Keywords: IL-5, eosinophilic asthma, reslizumab, chronic obstructive pulmonary disease, MAPK, Janus kinases
- Published
- 2016
23. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
- Author
-
PELAIA, GIROLAMO, Vatrella,Alessandro, Busceti,Maria Teresa, GALLELLI,LUCA, Calabrese,Cecilia, Terracciano,Rosa, Lombardo,Nicola, and Maselli,Rosario
- Subjects
Therapeutics and Clinical Risk Management ,hormones, hormone substitutes, and hormone antagonists - Abstract
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Cecilia Calabrese,4 Rosa Terracciano,3 Nicola Lombardo,1 Rosario Maselli11Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro, 2Departmentof Medicine and Surgery, University of Salerno, Salerno, 3Department of Health Science, Magna Græcia University of Catanzaro, Catanzaro, 4Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Naples, ItalyAbstract: Bronchodilators are the most important drugs used for the treatment of chronic obstructive pulmonary disease (COPD). In particular, these therapeutic agents are mostly long-acting compounds utilized via inhalation, and include LAMA (long-acting muscarinic receptor antagonists) and LABA (long-acting β2-adrenoceptor agonists). Because LAMA and LABA induce bronchodilation by distinct mechanisms of action, LABA/LAMA combinations provide a reciprocal potentiation of the pharmacological effects caused by each component. Hence, many COPD patients who do not achieve a satisfactory control of their symptoms using a single, either LAMA or LABA bronchodilator, can experience relevant benefits with the use of LAMA/LABA fixed combinations. Many different LAMA/LABA combinations have been recently developed and evaluated in randomized clinical trials. In this context, our review focuses on the pharmacological mechanisms underpinning the bronchodilation elicited by the LAMA tiotropium bromide and the LABA olodaterol. We also discuss the results of the most important clinical studies carried out in COPD patients to assess the efficacy and safety of tiotropium/olodaterol combinations.Keywords: LAMA, LABA, tiotropium, olodaterol, dual bronchodilation, tiotropium/olodaterol combinations
- Published
- 2015
24. Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
- Author
-
Pelaia, Girolamo, Vatrella, Alessandro, Busceti, Maria Teresa, Gallelli, Luca, Calabrese, Cecilia, Terracciano, Rosa, and Maselli, Rosario
- Subjects
Article Subject - Abstract
Asthma is a phenotypically heterogeneous chronic disease of the airways, characterized by either predominant eosinophilic or neutrophilic, or even mixed eosinophilic/neutrophilic inflammatory patterns. Eosinophilic inflammation can be associated with the whole spectrum of asthma severity, ranging from mild-to-moderate to severe uncontrolled disease, whereas neutrophilic inflammation occurs mostly in more severe asthma. Eosinophilic asthma includes either allergic or nonallergic phenotypes underlying immune responses mediated by T helper (Th)2 cell-derived cytokines, whilst neutrophilic asthma is mostly dependent on Th17 cell-induced mechanisms. These immune-inflammatory profiles develop as a consequence of a functional impairment of T regulatory (Treg) lymphocytes, which promotes the activation of dendritic cells directing the differentiation of distinct Th cell subsets. The recent advances in the knowledge of the cellular and molecular mechanisms underlying asthmatic inflammation are contributing to the identification of novel therapeutic targets, potentially suitable for the implementation of future improvements in antiasthma pharmacologic treatments.
- Published
- 2015
- Full Text
- View/download PDF
25. Application of Proteomics and Peptidomics to COPD
- Author
-
Pelaia, Girolamo, Terracciano, Rosa, Vatrella, Alessandro, Gallelli, Luca, Busceti, Maria Teresa, Calabrese, Cecilia, Stellato, Cristiana, Savino, Rocco, and Maselli, Rosario
- Subjects
Article Subject ,respiratory system ,respiratory tract diseases - Abstract
Chronic obstructive pulmonary disease (COPD) is a complex disorder involving both airways and lung parenchyma, usually associated with progressive and poorly reversible airflow limitation. In order to better characterize the phenotypic heterogeneity and the prognosis of patients with COPD, there is currently an urgent need for discovery and validation of reliable disease biomarkers. Within this context, proteomic and peptidomic techniques are emerging as very valuable tools that can be applied to both systemic and pulmonary samples, including peripheral blood, induced sputum, exhaled breath condensate, bronchoalveolar lavage fluid, and lung tissues. Identification of COPD biomarkers by means of proteomic and peptidomic approaches can thus also lead to discovery of new molecular targets potentially useful to improve and personalize the therapeutic management of this widespread respiratory disease.
- Published
- 2014
- Full Text
- View/download PDF
26. Role of biologics in severe eosinophilic asthma – focus on reslizumab
- Author
-
Pelaia, Girolamo, primary, Vatrella, Alessandro, additional, Busceti, Maria Teresa, additional, Gallelli, Luca, additional, Preianò, Mariaimmacolata, additional, Lombardo, Nicola, additional, Terracciano, Rosa, additional, and Maselli, Rosario, additional
- Published
- 2016
- Full Text
- View/download PDF
27. Update on Anticytokine Treatment for Asthma
- Author
-
Gallelli, Luca, Busceti, Maria Teresa, Vatrella, Alessandro, Maselli, Rosario, and Pelaia, Girolamo
- Subjects
Article Subject - Abstract
Current advances in the knowledge of asthma pathobiology suggest that anticytokine therapies can be potentially useful for the treatment of this complex and heterogeneous airway disease. Recent evidence is accumulating in support of the efficacy of anti-IL-4, anti-IL-5, and anti-IL-13 drugs. Therefore, these new developments are now changing the global scenario of antiasthma therapies, especially with regard to more severe disease. Current findings referring to variability of individual therapeutic responses highlight that the different asthma subtypes need to be well characterized, in order to implement phenotype-targeted treatments which in the near future will hopefully be mainly based on cytokine-directed biologics.
- Published
- 2013
- Full Text
- View/download PDF
28. Review: Omalizumab in the treatment of severe asthma: efficacy and current problems
- Author
-
Pelaia, Girolamo, primary, Renda, Teresa, additional, Romeo, Pasquale, additional, Busceti, Maria Teresa, additional, and Maselli, Rosario, additional
- Published
- 2008
- Full Text
- View/download PDF
29. Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma
- Author
-
Pelaia, Girolamo, primary, Renda, Teresa, additional, Gallelli, Luca, additional, Vatrella, Alessandro, additional, Busceti, Maria Teresa, additional, Agati, Sergio, additional, Caputi, Mario, additional, Cazzola, Mario, additional, Maselli, Rosario, additional, and Marsico, Serafino A., additional
- Published
- 2008
- Full Text
- View/download PDF
30. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey
- Author
-
Giorgio Walter Canonica, Fulvio Braido, Angelo Corsico, Elena Bacci, Paola Rogliani, Giuseppe Girbino, Pierluigi Paggiaro, Fabiano Di Marco, Pierachille Santus, Michela Bellocchia, Maria D'Amato, Amelia Grosso, Ilaria Baiardini, Pietro Pirina, Manuela Latorre, Alfio Proietto, Stefano Centanni, Paolo Solidoro, Maria Teresa Busceti, Garuti Silvia, Maria Cristina Colanardi, Girolamo Pelaia, Umberto Zuccon, Nicola Scichilone, Giorgia Molinengo, Maria Pia Foschino Barbaro, Francesco Blasi, Silvia Terraneo, Josuel Ora, Caterina Bucca, Carlo Mereu, Pietro Alleri, Alida Benfante, Marta Ferrari, Carlo Barbetta, Alessandro G. Fois, Giovanni Florio, Sara Maniscalco, Marco Contoli, Francesco Mazza, Francesca Simioli, Dottorini Marco, Vincenzo Patella, Braido, Fulvio, Baiardini, Ilaria, Alleri, Pietro, Bacci, Elena, Barbetta, Carlo, Bellocchia, Michela, Benfante, Alida, Blasi, Francesco, Bucca, Caterina, Busceti, Maria Teresa, Centanni, Stefano, Colanardi, Maria Cristina, Contoli, Marco, Corsico, Angelo, D'Amato, Maria, Di Marco, Fabiano, Marco, Dottorini, Ferrari, Marta, Florio, Giovanni, Fois, Alessandro Giuseppe, Foschino Barbaro, Maria Pia, Silvia, Garuti, Girbino, Giuseppe, Grosso, Amelia, Latorre, Manuela, Maniscalco, Sara, Mazza, Francesco, Mereu, Carlo, Molinengo, Giorgia, Ora, Josuel, Paggiaro, Pierluigi, Patella, Vincenzo, Pelaia, Girolamo, Pirina, Pietro, Proietto, Alfio, Rogliani, Paola, Santus, Pierachille, Scichilone, Nicola, Simioli, Francesca, Solidoro, Paolo, Terraneo, Silvia, Zuccon, Umberto, and Canonica, Giorgio Walter
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Concordance ,Socio-culturale ,Practice Patterns ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Retrospective Studie ,Surveys and Questionnaires ,Severity of illness ,Health care ,medicine ,Surveys and Questionnaire ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Aged ,Asthma ,Female ,Italy ,Middle Aged ,Retrospective Studies ,Quality of Life ,Specialization ,Modalities ,Physicians' ,business.industry ,Biochemistry (medical) ,Retrospective cohort study ,medicine.disease ,030228 respiratory system ,Test score ,Family medicine ,Physical therapy ,business ,Human - Abstract
Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected using an ad hoc questionnaire developed by a group of specialists selected by the Italian Pneumology Society/Italian Respiratory Society. Results The records of 557 patients were analyzed. In the next few years, specialists are expected to focus their activity patients with more severe disease and will be responsible for selection of patients for personalized biological therapy; however, only 20% of patients attending Italian specialist surgery can be considered severe. In 84.4% of cases, the visit was a follow-up visit requested in 82.2% of cases by the specialist him/herself. The Asthma Control Test is used only in 65% of patients. When available, a significant association has been observed between the test score and asthma control as judged by the physician, although concordance was only moderate (κ = 0.68). Asthma was considered uncontrolled by the specialist managing the case in 29.1% of patients; nevertheless, treatment was not stepped up in uncontrolled or partly controlled patients (modified in only 37.2% of patients). Conclusions The results of this survey support re-evaluation of asthma management by Italian specialists. More resources should be made available for the initial visit and for more severely ill patients. In addition, more extensive use should be made of validated tools, and available drugs should be used more appropriately.
- Published
- 2017
31. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma
- Author
-
Maria Teresa Busceti, Maria Gabriella Matera, Alessandro Vatrella, Rosario Maselli, Rosa Terracciano, Francesco Fabiano, Girolamo Pelaia, Pelaia, Girolamo, Vatrella, Alessandro, Busceti, Maria Teresa, Fabiano, Francesco, Terracciano, Rosa, Matera, Maria Gabriella, and Maselli, Rosario
- Subjects
0301 basic medicine ,Budesonide ,Pulmonary and Respiratory Medicine ,Asthma treatment ,Pharmacology ,Severity of Illness Index ,03 medical and health sciences ,Glucocorticoid ,Disease severity ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Anti-Asthmatic Agents ,Asthma ,Glucocorticoids ,Biochemistry (medical) ,business.industry ,Therapeutic effect ,medicine.disease ,respiratory tract diseases ,Bronchodilator Agents ,Clinical Practice ,030104 developmental biology ,Immunology ,business ,medicine.drug - Abstract
Inhaled glucocorticoids are the mainstay of asthma treatment. Indeed, such therapeutic agents effectively interfere with many pathogenic circuits underpinning asthma. Among these drugs, during the last decades budesonide has been probably the most used molecule in both experimental studies and clinical practice. Therefore, a large body of evidence clearly shows that budesonide, either alone or in combination with long-acting bronchodilators, provides a successful control of asthma in many patients ranging throughout the overall spectrum of disease severity. These excellent therapeutic properties of budesonide basically depend on its molecular mechanisms of action, capable of inhibiting within the airways the activity of multiple immune-inflammatory and structural cells involved in asthma pathobiology.
- Published
- 2016
32. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
- Author
-
Pelaia C, Benfante A, Busceti MT, Caiaffa MF, Campisi R, Carpagnano GE, Crimi N, D'Amato M, Foschino Barbaro MP, Maglio A, Minenna E, Nolasco S, Paglino G, Papia F, Pelaia G, Portacci A, Ricciardi L, Scichilone N, Scioscia G, Triggiani M, Valenti G, Vatrella A, and Crimi C
- Subjects
- Humans, Inflammation, Chronic Disease, Rhinitis complications, Rhinitis drug therapy, Nasal Polyps complications, Nasal Polyps drug therapy, Sinusitis complications, Sinusitis drug therapy, Asthma complications, Asthma diagnosis, Asthma drug therapy, Hypersensitivity, Immediate
- Abstract
Background: The efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation., Objective: To assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence., Methods: Clinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP., Results: Among the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p < 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p < 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 ± 20.32 to 19.76 ± 12.76 (p < 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p < 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p < 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p < 0.01)., Conclusion: Our results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Pelaia, Benfante, Busceti, Caiaffa, Campisi, Carpagnano, Crimi, D’Amato, Foschino Barbaro, Maglio, Minenna, Nolasco, Paglino, Papia, Pelaia, Portacci, Ricciardi, Scichilone, Scioscia, Triggiani, Valenti, Vatrella and Crimi.)
- Published
- 2023
- Full Text
- View/download PDF
33. New treatments for asthma: From the pathogenic role of prostaglandin D 2 to the therapeutic effects of fevipiprant.
- Author
-
Pelaia C, Crimi C, Vatrella A, Busceti MT, Gaudio A, Garofalo E, Bruni A, Terracciano R, and Pelaia G
- Subjects
- Animals, Asthma immunology, Humans, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Indoleacetic Acids therapeutic use, Prostaglandin D2 immunology, Pyridines therapeutic use
- Abstract
Prostaglandin D
2 (PGD2 ) is a pleiotropic mediator, significantly involved in the pathogenesis of type 2 (T2) asthma because of its biologic actions exerted on both immune/inflammatory and airway structural cells. In particular, the pro-inflammatory and pro-remodelling effects of PGD2 are mainly mediated by stimulation of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). This receptor is the target of the oral competitive antagonist fevipiprant, which on the basis of recent phase II studies is emerging as a potential very promising anti-asthma drug. Indeed, fevipiprant appears to be safe and effective, especially in consideration of its ability to inhibit eosinophilic bronchial inflammation and improve forced expiratory volume in one second (FEV1 ). Further ongoing phase III trials will definitely clarify if fevipiprant can prospectively become a valid option for an efficacious add-on treatment of moderate-to-severe T2-high asthma., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
34. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
- Author
-
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, and Maselli R
- Subjects
- Anti-Asthmatic Agents administration & dosage, Anti-Asthmatic Agents adverse effects, Anti-Asthmatic Agents pharmacology, Antibodies, Anti-Idiotypic administration & dosage, Antibodies, Anti-Idiotypic adverse effects, Antibodies, Anti-Idiotypic pharmacology, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized pharmacology, Asthma immunology, Clinical Trials as Topic, Humans, Immunoglobulin E immunology, Omalizumab, Severity of Illness Index, Anti-Asthmatic Agents therapeutic use, Antibodies, Anti-Idiotypic therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Asthma drug therapy, Immunoglobulin E blood, Receptors, IgE antagonists & inhibitors
- Abstract
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
- Published
- 2015
- Full Text
- View/download PDF
35. Update on optimal use of omalizumab in management of asthma.
- Author
-
Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, and Vatrella A
- Abstract
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.
- Published
- 2011
- Full Text
- View/download PDF
36. Omalizumab in the treatment of severe asthma: efficacy and current problems.
- Author
-
Pelaia G, Renda T, Romeo P, Busceti MT, and Maselli R
- Subjects
- Anti-Asthmatic Agents adverse effects, Anti-Asthmatic Agents immunology, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal immunology, Antibodies, Monoclonal, Humanized, Asthma immunology, Asthma physiopathology, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Immunoglobulin E immunology, Omalizumab, Severity of Illness Index, Anti-Asthmatic Agents administration & dosage, Antibodies, Monoclonal administration & dosage, Asthma drug therapy
- Abstract
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high-affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma, inadequately controlled by high doses of standard inhaled treatments.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.